IMPACT model, 闡述為何 CHD變少，是risk facotr 變少，加上treatment imrpovement

http://docs.google.com/present/edit?id=0AW78nGJMQBk7ZGc1d3FjYmpfMTIyZmY0c3E5aGM&hl=en

Staying Ahead of the Curve

Researchers relate trends in cardiovascular prevention and treatment to recent improvements in mortality from coronary heart disease.

Debate surrounds the relative contributions of preventive and treatment strategies to recent reductions in deaths from coronary heart disease (CHD). These investigators used epidemiologic data from Ontario, Canada, and the IMPACT CHD mortality model (slide presentation available on the Liverpool University website) to address this issue.

Between 1994 and 2005, the age-adjusted CHD mortality rate in Ontario residents aged 25–84 fell 35%, from 191 to 125 deaths per 100,000 residents. Changes in population risk factors accounted for 48% of the decrease, whereas medical and surgical treatments accounted for 43% (9% of the decrease was unaccounted for by variables included in the model). The 75-to-84-year-old age group had the greatest absolute reduction in CHD deaths. Among patients receiving treatment for various conditions, the greatest mortality reduction occurred in those with stable coronary artery disease. Improvements in the treatment of patients with acute myocardial infarction were responsible for 8% of the decrease. Increases in diabetes prevalence and body-mass index offset the mortality reductions (by 6% and 2%, respectively).

Comment: These findings indicate that reductions in CHD mortality are attributable to improvements in both prevention and treatment. However, as obesity and diabetes rates continue to grow, we could see some retrenchment in these gains during the coming decades.

— Harlan M. Krumholz, MD, SM

Published in Journal Watch Cardiology June 2, 2010

Citation(s):

Wijeysundera HC et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010 May 12; 303:1841.

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

白宮為了掌控醫療費用，傾向大型醫療，個體戶勢必受挫

所以一旦政府介入，中外醫療提供者都傾向大型化…… independent practice -> dreaming 診所評鑑??應該擋住! http://www.medscape.com/viewarticle/727420 Physicians Say White House Should Not Write Off Small Practices August 24, 2010 — In a newly published article, the White House is advising physicians to accept a life in Big Medicine — as a hospital employee or member of a large group practice — in the wake of healthcare reform. Some leaders of organized medicine, however, are objecting to the government message. "We're not ready to write off the small practices," J. Fred Ralston Jr, MD, president of the American College of Physicians, told Medscape Medical News. "We think there needs to be more than one delivery model." "America is not a one-size-fits-all country," added M. Todd Williamson, MD, a neurologist from Lawrenceville, Georgia, and spokesperson for a coalition of medical societies opposed to the new healthcare reform law, now called the Affordable Care Act. Dr. Ralston and Dr.
閱讀完整內容

老美接受LTBI treatment的人，不到一半完治，和duration成正比

This study shows that although acceptance of LTBI treatment is relatively high (83%), the proportion completing is low (47%). When the product of these two proportions is calculated, we see that completion was achieved by only 39% of persons who were offered LTBI treatment. The major risk factor for noncompletion was being prescribed the 9-month INH regimen. As shown in Figure 1, when the proportions completing the three most commonly prescribed regimens are compared, it can be seen that there is an inverse relationship between length of the regimen prescribed and the proportion completing treatment. The increased completion that we observed with the 4-month rifampin regimen is consistent with previous reports.[18–20] It is of interest to note that if completion of the 9-month regimen were defined as completion of at least 6 months of INH, the noncompletion rate of the 9-month regimen, 42.9%, would have been almost identical to that of the 6-month regimen, 44.8%. Thus, prescribing the
閱讀完整內容